Publications by authors named "M Dalsgaard"
Background: Indocyanine green fluorescence angiography (ICG-FA) may reduce perfusion-related complications of gastrointestinal anastomosis. Software implementations for quantifying ICG-FA are emerging to overcome a subjective interpretation of the technology. Comparison between quantification algorithms is needed to judge its external validity.
View Article and Find Full Text PDFIntroduction: Patients triaged as non-urgent in the emergency department constitute a diverse group with a low mortality rate assumed to be able to wait three hours for a physician. Little is known about the causes of death of non-urgent patients who die shortly after admission. We examined whether deaths among non-urgent patients were preventable.
View Article and Find Full Text PDFBackground And Aims: In the Partial Oral Treatment of Endocarditis (POET) trial, stabilized patients with left-sided infective endocarditis (IE) were randomized to oral step-down antibiotic therapy (PO) or conventional continued intravenous antibiotic treatment (IV), showing non-inferiority after 6 months. In this study, the first guideline-driven clinical implementation of the oral step-down POET regimen was examined.
Methods: Patients with IE, caused by Staphylococcus aureus, Enterococcus faecalis, Streptococcus spp.
Article Synopsis
- Transcatheter aortic valve replacement (TAVR) is effective for severe aortic valve stenosis, even in patients with low left ventricular ejection fraction (LVEF), but the effectiveness of specific TAVR devices in this group is unclear.
- The LOSTAVI study analyzed 923 patients with varying levels of LVEF (<25%, 25-30%, 31-35%) and found that while in-hospital mortality rates were similar, patients with extremely low LVEF experienced more major adverse events.
- At 12 months, reduced LVEF significantly impacted mortality and adverse events, confirming its importance in patient prognosis, while TAVR device type did not influence these outcomes.*
Importance: ApTOLL is a TLR4 antagonist with proven preclinical neuroprotective effect and a safe profile in healthy volunteers.
Objective: To assess the safety and efficacy of ApTOLL in combination with endovascular treatment (EVT) for patients with ischemic stroke.
Design, Setting, And Participants: This phase 1b/2a, double-blind, randomized, placebo-controlled study was conducted at 15 sites in Spain and France from 2020 to 2022.